1. Home
  2. Analysis

Hepatic function abnormal and drugs of ingredients of bendamustine (a real world drug study)


Summary:

Hepatic function abnormal is found among people who take drugs with ingredients of bendamustine, especially for people who are male, 60+ old , have been taking the drugs for < 1 month. This phase IV clinical study is created by eHealthMe based on reports of 9,503 people who have side effects when taking drugs with ingredients of bendamustine from the FDA, and is updated regularly.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Bendamustine.

On Jun, 22, 2026

9,503 people reported to have side effects when taking drugs with ingredients of bendamustine.
Among them, 26 people (0.27%) have Hepatic function abnormal

What is Hepatic function abnormal?

Hepatic function abnormal is found to be associated with 1,444 drugs and 2,019 conditions by eHealthMe. Check the latest studies of Hepatic function abnormal.

Number of reports submitted per year:

Could drugs with ingredients of bendamustine cause Hepatic function abnormal?

Time on drugs with ingredients of bendamustine when people have Hepatic function abnormal *:

  • < 1 month: 72.73 %
  • 1 - 6 months: 27.27 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Hepatic function abnormal when taking drugs with ingredients of bendamustine *:

  • female: 21.74 %
  • male: 78.26 %

Age of people who have Hepatic function abnormal when taking drugs with ingredients of bendamustine *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 5.5600000000000005 %
  • 40-49: 11.11 %
  • 50-59: 22.22 %
  • 60+: 61.11 %

Conditions people have *:

You may use this to check any potential undetected conditions.

  1. Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 16 people, 61.54%
  2. Burkitt Lymphoma (cancer of the lymphatic system): 3 people, 11.54%
  3. Extranodal Marginal Zone B-Cell Lymphoma (Malt Type) (cancer originating from b cells in the marginal zone of the malt): 2 people, 7.69%
  4. Diffuse Large B-Cell Lymphoma Stage Ii (cancer of b cells, a type of white blood cell-stage ii): 2 people, 7.69%
  5. B-Cell Lymphoma Refractory (blood cancer affecting b cells-relapsed): 1 person, 3.85%

Other drugs people take *:

You may use this to check any potential interacting drugs.

  1. Cyclophosphamide: 13 people, 50.00%
  2. Prednisone: 13 people, 50.00%
  3. Carboplatin: 12 people, 46.15%
  4. Etoposide: 12 people, 46.15%
  5. Ifosfamide: 10 people, 38.46%
  6. Oxaliplatin: 8 people, 30.77%
  7. Gemcitabine: 7 people, 26.92%
  8. Lenalidomide: 5 people, 19.23%
  9. Mitoxantrone: 3 people, 11.54%
  10. Doxorubicin Hydrochloride: 3 people, 11.54%

Other side effects people have besides Hepatic function abnormal *:

You may use this to check any potential undetected side effects.

  1. Blood Lactate Dehydrogenase Increased: 11 people, 42.31%
  2. Diffuse Large B-Cell Lymphoma Recurrent (recurrent cancer of b cells, a type of white blood cell): 9 people, 34.62%
  3. Fungal Infection: 9 people, 34.62%
  4. Thrombocytopenia (decrease of platelets in blood): 6 people, 23.08%
  5. Pneumonia: 5 people, 19.23%
  6. Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 4 people, 15.38%
  7. Leukopenia (less number of white blood cells in blood): 4 people, 15.38%
  8. Weakness: 4 people, 15.38%
  9. Anaemia (lack of blood): 4 people, 15.38%
  10. Renal Impairment (severely reduced kidney function): 4 people, 15.38%

* Approximation only. Some reports may have incomplete information.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

Drugs with ingredients of bendamustine, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on bendamustine. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.